Selected transactions
Therapeutic Area
Exclusive Financial Advisor to Nicox for the sale of the remaining stake in VISUfarma to GHO Capital.
Exclusive Financial Advisor to Nicox for the Transfer of its European commercial operations to a newly-founded company focused on ophthalmic products in Europe.
Exclusive Financial Advisor to ERC for a share capital increase subscribed by UHNWI investors.
Exclusive Financial Advisor in the acquisition of the outstanding equity of Aciex Therapeutics, Inc., a private, US-based, ophthalmic development pharmaceutical company.
Exclusive Financial Advisor to NicOx SA on the acquisition of Laboratoires Doliage and concurrent entry into ancillary agreements with the Seller.
Exclusive Financial Advisor in the acquisition of Marinomed GmbH, a Biotechnology company developping anti-viral and immunological treatments, including Carragelose® anti-viral eye drop program.
Exclusive Financial Advisor to Alternext listed Novacyt SA on a merger with Lab21 Ltd.
Exclusive Financial Advisor to NicOx SA on the acquisition of Eupharmed S.r.l for an upfront consideration combined with a performance earn-out.
Exclusive Financial Advisor to Ekomir’s shareholders on the sale of the company to Valeant Pharmaceuticals.
Financial Advisor to Vemedia’s shareholders on the sale of a 78% stake to IK Investment Partners and a minority MBO to CEO.
Exclusive Financial Advisor to Italian healthcare company Scharper SpA on the sale of a majority stake to Italy-based group IdB Holding SpA.
Exclusive advisor to Vaxon Biotech on a global collaboration partnership, including a call option arrangement an upfront and several clinical performance milestones with a major US oncology player.